| abstract |
The present invention provides a compound represented by the general formula (I) of the present invention, which has EP 1 receptor antagonism: n nwherein A represents a pyridine ring, a furan ring, or the like; Y 1 represents a C 1-6 alkylene group; Y 2 represents a single bond or the like; R 1 represents —C(═O)—NH—SO 2 R 6 , an acidic 5-membered hetero ring group, or the like; R 2 represents an optionally substituted phenyl group, an optionally substituted 5-membered aromatic heterocyclic group, or the like; R 3 represents a halogen atom, a C 1-6 alkoxy group, or the like; R 4 represents a hydrogen atom, a halogen atom, or the like; R 5 represents a hydrogen atom or the like; and R 6 represents a C 1-6 alkyl group or the like], and a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs. |